JP2004502638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502638A5 JP2004502638A5 JP2001547043A JP2001547043A JP2004502638A5 JP 2004502638 A5 JP2004502638 A5 JP 2004502638A5 JP 2001547043 A JP2001547043 A JP 2001547043A JP 2001547043 A JP2001547043 A JP 2001547043A JP 2004502638 A5 JP2004502638 A5 JP 2004502638A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- alkyl
- oxa
- hydroxyalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229930003316 Vitamin D Natural products 0.000 description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- -1 vitamin D compound Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 0 CCC(C)(C(*)CC1)C1=C Chemical compound CCC(C)(C(*)CC1)C1=C 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 個別投与または単一組成物としての投与のための有効量の生物学的活性ビタミンD化合物および有効量のインターロイキン-10を含み、組み合わせ用量が重篤な高カルシウム血症を引き起こさない、炎症性腸疾患の症状の治療および予防のための薬学的組み合わせ。
【請求項２】 生物学的活性ビタミンD化合物が、ビタミンD、1α,25-(OH)2-16-エン-D3、1α,25-(OH)2-24-オキソ-16-エン-D3、1α,24R(OH)2-D3、1α,25(OH)2-22-オキサ-D3、20-エピ-22-オキサ-24a,24b,-ジホモ-1α,25(OH)2-D3、20-エピ-22-オキサ-24a,26a,27a,-トリホモ-1a,25(OH)2-D3、20-エピ-22-オキサ-24ホモ-1α,25(OH)2-D3、および1,25-(OH)2-16,23E-ジエン-26-トリフルオロ-19-ノル-D3からなる群より選択される、請求項1記載の組み合わせ。
【請求項３】 生物学的活性ビタミンD化合物が以下の式によって表される類似体より選択される、請求項1記載の組み合わせ：
式中、X1およびX2はそれぞれ水素およびアシルからなる群より選択される；
Y1およびY2はHでもよく、または一方がO-アリールもしくはO-アルキルであって他方が水素であり、β配置もしくはα配置をとってもよい：Z1およびZ2はいずれもHである、またはZ1およびZ2はまとめてCH2である；ならびに
Rはアルキル基、ヒドロキシアルキル基もしくはフルオロアルキル基である、またはRは以下の側鎖であってもよい：
式中、（a）はS配置またはR配置をとることができ、R1は水素、ヒドロキシまたはO-アシルであり、R2およびR3はそれぞれアルキル基、ヒドロキシアルキル基およびフルオロアルキル基からなる群より選択される、またはまとめると--(CH2)m--基であり、式中、mは2〜5の値を有する整数であり、R4は水素、ヒドロキシ、フッ素、O-アシル、アルキル、ヒドロキシアルキルおよびフルオロアルキルからなる群より選択され、R5は水素、ヒドロキシ、フッ素、アルキル、ヒドロキシアルキルおよびフルオロアルキルからなる群より選択される、またはR4およびR5はまとめて二重結合性の酸素であり、R6およびR7はまとめて炭素-炭素二重結合を形成し、R8はHまたはCH3であってよく、nは1〜5の値をとる整数であり、側鎖の20位、22位または23位のいずれか1つの炭素をO、SまたはN原子によって置換してもよい。
【請求項４】 炎症性腸疾患の症状の治療および予防のための医薬の製造における、有効量の生物学的活性ビタミンD化合物および有効量のインターロイキン-10の使用であって、医薬が重篤な高カルシウム血症を引き起こさない、使用。
【請求項５】 医薬が高カルシウム血症の症状を引き起こさない、請求項4記載の使用。
【請求項１】 個別投与または単一組成物としての投与のための有効量の生物学的活性ビタミンD化合物および有効量のインターロイキン-10を含み、組み合わせ用量が重篤な高カルシウム血症を引き起こさない、炎症性腸疾患の症状の治療および予防のための薬学的組み合わせ。
【請求項２】 生物学的活性ビタミンD化合物が、ビタミンD、1α,25-(OH)2-16-エン-D3、1α,25-(OH)2-24-オキソ-16-エン-D3、1α,24R(OH)2-D3、1α,25(OH)2-22-オキサ-D3、20-エピ-22-オキサ-24a,24b,-ジホモ-1α,25(OH)2-D3、20-エピ-22-オキサ-24a,26a,27a,-トリホモ-1a,25(OH)2-D3、20-エピ-22-オキサ-24ホモ-1α,25(OH)2-D3、および1,25-(OH)2-16,23E-ジエン-26-トリフルオロ-19-ノル-D3からなる群より選択される、請求項1記載の組み合わせ。
【請求項３】 生物学的活性ビタミンD化合物が以下の式によって表される類似体より選択される、請求項1記載の組み合わせ：
Y1およびY2はHでもよく、または一方がO-アリールもしくはO-アルキルであって他方が水素であり、β配置もしくはα配置をとってもよい：Z1およびZ2はいずれもHである、またはZ1およびZ2はまとめてCH2である；ならびに
Rはアルキル基、ヒドロキシアルキル基もしくはフルオロアルキル基である、またはRは以下の側鎖であってもよい：
【請求項４】 炎症性腸疾患の症状の治療および予防のための医薬の製造における、有効量の生物学的活性ビタミンD化合物および有効量のインターロイキン-10の使用であって、医薬が重篤な高カルシウム血症を引き起こさない、使用。
【請求項５】 医薬が高カルシウム血症の症状を引き起こさない、請求項4記載の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/469,985 US6358939B1 (en) | 1999-12-21 | 1999-12-21 | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
| PCT/US2000/034913 WO2001046132A1 (en) | 1999-12-21 | 2000-12-21 | Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004502638A JP2004502638A (ja) | 2004-01-29 |
| JP2004502638A5 true JP2004502638A5 (ja) | 2008-01-31 |
Family
ID=23865828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001547043A Withdrawn JP2004502638A (ja) | 1999-12-21 | 2000-12-21 | 炎症性腸疾患の予防および治療のための生物学的活性ビタミンｄ化合物の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6358939B1 (ja) |
| EP (1) | EP1240136A4 (ja) |
| JP (1) | JP2004502638A (ja) |
| KR (1) | KR100660508B1 (ja) |
| AU (1) | AU781113B2 (ja) |
| CA (1) | CA2395200A1 (ja) |
| MX (1) | MXPA02006257A (ja) |
| NO (1) | NO326517B1 (ja) |
| WO (1) | WO2001046132A1 (ja) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| EP1233942A2 (en) * | 1999-12-02 | 2002-08-28 | The Penn State Research Foundation | Treatment of inflammatory bowel disease with vitamin d compounds |
| US6989377B2 (en) * | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| AU2002220029B2 (en) * | 2000-11-14 | 2007-09-06 | Techlab, Inc. | Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker |
| US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| WO2004063345A2 (en) * | 2003-01-10 | 2004-07-29 | Eli Lilly And Company | Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators |
| EP1603530A1 (en) * | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| GB0307865D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| US20050148557A1 (en) * | 2003-07-29 | 2005-07-07 | Jin Tian | Use of Vitamin Ds to treat kidney disease |
| US20050192255A1 (en) * | 2003-07-30 | 2005-09-01 | Jin Tian | Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease |
| US20050209203A1 (en) * | 2003-07-30 | 2005-09-22 | Jin Tian | Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease |
| US20060171983A1 (en) * | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
| US7704980B2 (en) * | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| GB0513984D0 (en) * | 2005-07-07 | 2005-08-17 | Teva Pharma | Dosage form |
| EP2129382A4 (en) | 2007-02-21 | 2011-01-19 | Univ Michigan | COMPOSITIONS AND METHODS FOR TRANQUILIZATION OF THE CARDIAC MUSCLE |
| WO2008121386A2 (en) * | 2007-03-30 | 2008-10-09 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
| JP2010524973A (ja) * | 2007-04-18 | 2010-07-22 | ジョンズ ホプキンス ユニバーシティ | カルシトリオールの低カルシウム血性、高抗増殖性類似体 |
| US8318708B2 (en) * | 2007-11-06 | 2012-11-27 | Salk Institute For Biological Studies | Use of vitamin D receptor agonists, ligands, and precursors to treat pancreatic fibrosis |
| WO2009062132A2 (en) | 2007-11-09 | 2009-05-14 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
| CN107019795A (zh) * | 2009-01-27 | 2017-08-08 | 博格有限责任公司 | 用于减轻与化疗有关的副作用的维生素d3化合物 |
| MX366076B (es) | 2009-08-14 | 2019-06-27 | Berg Llc | Vitamina d3 y analogos de la misma para tratar alopecia. |
| WO2011063241A1 (en) | 2009-11-20 | 2011-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| WO2011127302A2 (en) | 2010-04-07 | 2011-10-13 | Yue Shen | Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems |
| JP6067550B2 (ja) | 2010-04-13 | 2017-01-25 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
| WO2012103532A1 (en) * | 2011-01-28 | 2012-08-02 | Mazmanian Sarkis K | Combinatorial vitamin d and probiotic therapy for inflammatory bowel disease |
| WO2013009945A1 (en) | 2011-07-12 | 2013-01-17 | The Brigham And Women's Hospital, Inc. | Lipid-containing psa compositions, methods of isolation and methods of use thereof |
| HUE025567T2 (en) * | 2011-08-19 | 2016-02-29 | Maria Clementine Martin Klosterfrau Vertriebsges Mbh | Agents containing vasoconstrictors for combination therapy |
| CA2909941A1 (en) | 2013-04-24 | 2014-10-30 | Salk Institute For Biological Studies | Vitamin d receptor/smad genomic circuit gates fibrotic response |
| EP2994161B1 (en) | 2013-05-10 | 2020-10-28 | California Institute of Technology | Probiotic prevention and treatment of colon cancer |
| NZ714801A (en) | 2013-05-29 | 2021-07-30 | Berg Llc | Preventing or mitigating chemotherapy induced alopecia using vitamin d |
| CA2914487A1 (en) | 2013-06-05 | 2014-12-11 | Salk Institute For Biological Studies | Vitamin d receptor agonists to treat diseases involving cxcl12 activity |
| EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| KR102343093B1 (ko) | 2015-02-23 | 2021-12-24 | 삼성전자주식회사 | 식기 세척기 및 그 제어방법 |
| US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
| CN108135167B (zh) | 2015-08-19 | 2021-07-09 | 哈佛学院院长及董事 | 脂化psa组合物和方法 |
| WO2018014012A1 (en) | 2016-07-15 | 2018-01-18 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4312806A (en) | 1981-03-02 | 1982-01-26 | G. D. Searle & Co. | Method and compounds for treating inflammatory bowel disease |
| US4638043A (en) | 1984-11-13 | 1987-01-20 | Thermedics, Inc. | Drug release system |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US5518725A (en) | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
| US5824313A (en) | 1989-09-25 | 1998-10-20 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
| US5643602A (en) | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
| US5216002A (en) | 1989-12-21 | 1993-06-01 | Eli Lilly And Company | Method of treating inflammatory bowel disease |
| JP2811353B2 (ja) | 1990-07-06 | 1998-10-15 | ゼリア新薬工業株式会社 | 炎症性腸疾患予防・治療剤 |
| CA2049481A1 (en) | 1990-08-27 | 1992-02-28 | Jill Ann Panetta | Method of treating inflammatory bowel disease |
| US5391555A (en) | 1991-11-12 | 1995-02-21 | Miles Inc. | Methods for treating inflammatory bowel disease with leukotriene synthesis inhibitors |
| DE4141746A1 (de) | 1991-12-13 | 1993-06-17 | Schering Ag | 20-methyl-substituierte vitamin d-derivate |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| DK64592D0 (da) | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | Peptider til terapeutisk behandling |
| DE4221961A1 (de) * | 1992-06-30 | 1994-01-05 | Schering Ag | 22-En-25-oxa-Derivate in der Vitamin D-Reihe, Verfahren zu ihrer Herstellung, diese Derivate enthaltenen pharmazeutische Präparate sowie deren Verwendung als Arzneimittel |
| US5294630A (en) | 1992-07-07 | 1994-03-15 | Eli Lilly And Company | Treatment of inflammatory bowel disease |
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| IL107185A (en) * | 1992-10-06 | 1998-02-22 | Schering Ag | History of 52-carboxylic acid, processes for their preparation and pharmaceutical preparations containing them |
| GB9223061D0 (en) | 1992-11-04 | 1992-12-16 | Leo Pharm Prod Ltd | Chemical compounds |
| DK0813865T3 (da) | 1993-04-20 | 2001-11-19 | Hexal Ag | Plaster med virksomt stof |
| GB9309422D0 (en) | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
| GB9314400D0 (en) | 1993-07-12 | 1993-08-25 | Leo Pharm Prod Ltd | Produktionsaktieselskab) chemical compounds |
| GB9315253D0 (en) | 1993-07-23 | 1993-09-08 | Res Inst Medicine Chem | Chemical compounds |
| US5420109A (en) | 1993-11-12 | 1995-05-30 | Houghten Pharmaceuticals, Inc. | Cytokine restraining agents |
| GB9325415D0 (en) | 1993-12-13 | 1994-02-16 | Res Inst Medicine Chem | Chemical compounds |
| DE4405545A1 (de) * | 1994-02-22 | 1995-08-31 | Dietl Hans | Fettlösliche Vitamine enthaltende Zubereitung zur oralen Applikation |
| GB9405715D0 (en) | 1994-03-23 | 1994-05-11 | Res Inst Medicine Chem | Chemical compounds |
| GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| DK0717034T3 (da) | 1994-12-14 | 1999-10-18 | Duphar Int Res | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser |
| CA2210106A1 (en) | 1995-01-23 | 1996-08-01 | Yoshiyuki Ono | Vitamin d3 derivatives having a substituent at the 2-position |
| US5877168A (en) | 1995-02-10 | 1999-03-02 | Chugai Seiyaku Kabushiki Kaisha | Vitamin D derivative with substituent at the 2β-position |
| US5981597A (en) * | 1995-02-13 | 1999-11-09 | Trustees Of The University Of Pennsylvania | Differentiating agents for the treatment of inflammatory intestinal diseases |
| US5569680A (en) | 1995-02-13 | 1996-10-29 | Trustees Of The Univ. Of Penna | Method of treating inflammatory bowel disease with tributyrin |
| GB9509764D0 (en) | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| UA48973C2 (uk) | 1995-06-07 | 2002-09-16 | Орто-Макнейл Фармасьютікалз Інк. | Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції |
| US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
| US5851548A (en) | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
| US5952317A (en) | 1995-09-21 | 1999-09-14 | Wisconsin Alumni Research Foundation | Calcitriol derivatives and their uses |
| DE69606680T2 (de) | 1995-10-30 | 2000-08-17 | Hoffmann La Roche | 1-Alpha, 26-dihydroxy-D-homo-vitamin D3 |
| US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| AU710931B2 (en) | 1996-02-28 | 1999-09-30 | Sumitomo Pharmaceuticals Company, Limited | Crystalline vitamin D derivative |
| GB9607034D0 (en) | 1996-04-03 | 1996-06-05 | Leo Pharm Prod Ltd | Chemical compounds |
| EP0892638B1 (en) | 1996-04-04 | 2002-11-13 | Cilag AG | Liposome-based topical vitamin d formulation |
| US5891865A (en) | 1996-10-04 | 1999-04-06 | Wisconsin Alumni Research Foundation | Treatment of arthritic disease induced by infectious agents |
| NL1006072C2 (nl) | 1997-05-16 | 1998-11-17 | Jacobs Johannes J | Vergister voor het onder aërobe omstandigheden vergisten van dierlijke mest, inrichting en werkwijze voor het onder aërobe omstandigheden vergisten van dierlijke mest onder toepassing van een dergelijke vergister. |
| ATE322477T1 (de) * | 1997-05-16 | 2006-04-15 | Woman & Infants Hospital | 3-epi-vitamin d2 verbindungen und ihre anwendungen |
| EP0981523B1 (en) * | 1997-05-16 | 2005-12-07 | Woman & Infants Hospital | Cyclic ether vitamin d3 compounds, 1alpha (oh) 3-epi-vitamin d3 compounds and uses thereof |
| US5936105A (en) | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
| EP0927721A1 (de) * | 1997-12-17 | 1999-07-07 | Schering Aktiengesellschaft | Neue Vitamin D-Derivate mit Phosphoratomen in den Seitenketten, Zwischenprodukte bei ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln |
| US6214373B1 (en) * | 1999-10-07 | 2001-04-10 | Snowden-Sutton Associates, Inc. | Nutritional composition for treating inflammatory bowel diseases |
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| EP1233942A2 (en) * | 1999-12-02 | 2002-08-28 | The Penn State Research Foundation | Treatment of inflammatory bowel disease with vitamin d compounds |
| DE60105035T2 (de) * | 2000-09-08 | 2005-08-18 | Wisconsin Alumni Research Foundation, Madison | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol und seine therapeutische verwendungen |
-
1999
- 1999-12-21 US US09/469,985 patent/US6358939B1/en not_active Expired - Fee Related
-
2000
- 2000-12-21 EP EP00986687A patent/EP1240136A4/en not_active Ceased
- 2000-12-21 MX MXPA02006257A patent/MXPA02006257A/es active IP Right Grant
- 2000-12-21 JP JP2001547043A patent/JP2004502638A/ja not_active Withdrawn
- 2000-12-21 AU AU22878/01A patent/AU781113B2/en not_active Ceased
- 2000-12-21 CA CA002395200A patent/CA2395200A1/en not_active Abandoned
- 2000-12-21 KR KR1020027008018A patent/KR100660508B1/ko not_active IP Right Cessation
- 2000-12-21 WO PCT/US2000/034913 patent/WO2001046132A1/en active IP Right Grant
-
2001
- 2001-12-21 US US10/036,819 patent/US6858595B2/en not_active Expired - Fee Related
-
2002
- 2002-06-20 NO NO20022974A patent/NO326517B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502638A5 (ja) | ||
| EP0735859B1 (en) | A pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| HK1035665A1 (en) | Therapeutic compositions (II) | |
| JP2005526833A5 (ja) | ||
| CA2302700A1 (en) | New use for budesonide and formoterol | |
| ATE522211T1 (de) | Stabilisierte fibrat-mikropartikel | |
| JPH10503522A (ja) | 化学療法剤とともに使用するための防御性プロスタグランジン | |
| JP2005530743A5 (ja) | ||
| JPH0692847A (ja) | 骨粗鬆症治療剤 | |
| JP2006514092A5 (ja) | ||
| JP2003532640A5 (ja) | ||
| JP2002544227A5 (ja) | ||
| CA2483002A1 (en) | New pharmaceutical composition | |
| HK1087039A1 (en) | Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass | |
| US7214671B2 (en) | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases | |
| NORDENRAM et al. | A histopathologic study of replanted teeth with superficially demineralized root surfaces in Java monkeys | |
| KR100450293B1 (ko) | 만성장염의치료에유용한알카노일l-카르니틴의용도 | |
| ES2249013T3 (es) | Compuestos de 19-nor-vitamina d3 con actividad calcemica. | |
| HUP0002533A2 (hu) | Asztmaellenes gyógyszerhatóanyagok új kombinációja | |
| PL202567B1 (pl) | Zastosowanie ekstraktów z Ginkgo Biloba do wytwarzania leku do leczenia sarkopenii | |
| US5696103A (en) | Method for treating osteoporosis | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| RU2001131557A (ru) | Аналоги витамина D и их фармацевтическое использование | |
| JPH0121A (ja) | 骨の粗鬆化防止剤 | |
| JP2004506605A5 (ja) |